BBS-Bioactive Bone Substitutes Plc: Financial calendar and Annual General Meeting in 2024
Börskollen - Aktier, fonder och ekonominyheter

Börskollen

För dig med koll på börsen

Pressmeddelande

BBS-Bioactive Bone Substitutes Plc: Financial calendar and Annual General Meeting in 2024

BBS-Bioactive Bone Substitutes, Company announcement, 27 December 2023 at 5:00 p.m.

Financial calendar and Annual General Meeting in 2024

During the year 2024, BBS-Bioactive Bone Substitutes Plc (”BBS”) will publish the financial information as follows:

Financial Statements Release for the year 2023 will be published on Monday 26 February 2024 at 9.00 a.m.
Half-year financial report January-June 2024 will be published on Friday 30 August 2024
The Annual Report for the year 2023 will be published during the week 13/2024 the latest.

The Annual General Meeting is planned to be held on Tuesday 30 April 2024. Company’s Board of Directors will convene the meeting at a later date.


BBS-Bioactive Bone Substitutes Plc

Juliusz Rakowski, CEO



For more information, please contact:

Juliusz Rakowski, CEO
+358 50 448 5132
[email protected]


Certified Advisor:

Nordic Certified Adviser AB,
+46 70 551 67 29,
[email protected]


BBS in brief

BBS -Bioactive Bone Substitutes Plc is a orthobiology company that started its operations in 2003. We have developed a new product for the treatment of complex bone fractures and bone healing issues. Our goal is to provide next-generation medical products for the treatment of bone injuries in orthopedic surgery. In the pharmaceutical industry, the development and research work require perseverance and courage to innovate. We have a track record of over 20 years in this field. Our company is characterized by expertise, innovation, and dedicated employees who are passionate about their work. Our first developed product, ARTEBONE® Paste, is in the final stages of the CE marking process to enable its commercialization in the EU market. We are based in Oulu with a medical manufacturing facility in Reisjärvi, holding a manufacturing license. The company's headquarters are in Oulu, and we employ over 20 people.

BBS has been listed on Nasdaq First North Growth Market Finland since February 2018.

More information: www.bbs-artebone.fi


Nyheter om BBS-Bioactive Bone

Läses av andra just nu

Innehåller annonslänkar. Investeringar innebär risk (se här)

Tips: 50% rabatt hos fondroboten Opti

Dags att komma igång med sparande? Fondroboten Opti erbjuder en populär spartjänst som är perfekt för regelbundet månadssparande. Just nu får nya kunder som använder Börskollens unika kampanjkod BORSKOLLEN50 automatiskt 50 % rabatt på Optis avgift i 3 månader!

STÄNG X
Populär sparapp – över 500 000 nedladdningar
Många och höga externa omdömen
Högst grad av diversifiering
Perfekt för regelbundet månadssparande
KOM IGÅNG

Nya kunder som använder Börskollens unika kampanjkod BORSKOLLEN50 får automatiskt 50 procent rabatt på Optis avgift i 3 månader

Om aktien BBS-Bioactive Bone

Senaste nytt